a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors
Industry Biotechnology
A.I.dvisor tells us that CRDF and MGTX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CRDF and MGTX's prices will move in lockstep.
Ticker / NAME | Correlation To CRDF | 1D Price Change % | ||
---|---|---|---|---|
CRDF | 100% | -5.19% | ||
MGTX - CRDF | 33% Poorly correlated | -3.93% | ||
VRPX - CRDF | 32% Poorly correlated | +0.04% | ||
RGNX - CRDF | 32% Poorly correlated | -7.20% | ||
APGE - CRDF | 31% Poorly correlated | -5.41% | ||
SYRE - CRDF | 31% Poorly correlated | -7.48% | ||
More |
Ticker / NAME | Correlation To CRDF | 1D Price Change % |
---|---|---|
CRDF | 100% | -5.19% |
solid tumors theme (2 stocks) | 72% Closely correlated | -1.01% |
medicine theme (3 stocks) | 33% Loosely correlated | -1.26% |
cancer theme (87 stocks) | 29% Poorly correlated | +0.89% |
treatment theme (61 stocks) | 29% Poorly correlated | +0.91% |
oncology theme (18 stocks) | 28% Poorly correlated | +0.37% |
More |